
Vimal Prajapati, MD, FRCPC, DABD, highlights the durable efficacy of guselkumab, reassuring safety, and quality-of-life improvements in pediatric patients with moderate to severe plaque psoriasis.
Vimal Prajapati, MD, FRCPC, DABD, is a clinical associate professor at the University of Calgary and co-founder and co-director of the Skin Health & Wellness Centre, Dermphi Centre, Dermphi Shop, and Dermatology Research Institute

Vimal Prajapati, MD, FRCPC, DABD, highlights the durable efficacy of guselkumab, reassuring safety, and quality-of-life improvements in pediatric patients with moderate to severe plaque psoriasis.

Vimal Prajapati, MD, FRCPC, DABD, highlights guselkumab’s ability to achieve high levels of skin clearance in pediatric patients with moderate to severe plaque psoriasis.

Vimal Prajapati, MD, FRCPC, DABD, highlighted key findings from the THRIVE-AA trials, noting the efficacy of deuruxolitinib 8 mg BID, its favorable safety profile, and its positioning alongside other JAK inhibitors.

Vimal Prajapati, MD, FRCPC, DABD, reviews the mechanism of action, clinical trial outcomes, monitoring considerations, and safety profile of recently available deuruxolitinib.

Published: October 15th 2025 | Updated:

Published: September 19th 2025 | Updated:

Published: October 17th 2025 | Updated:

Published: September 2nd 2025 | Updated:

Published: September 4th 2025 | Updated: